As single agents or in combination with therapeutics, selective TOPK inhibitors have the capacity to potentiate the impact of DNA damaging agents by abrogating cell cycle checkpoint control and by re-establishing pro-apoptotic signalling in resistant tumours. The gene discussed is PBK; the disease is neoplasm.